跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT03837548
NCT03837548Unknown不适用

A Phase 1 Double-Blind Crossover Comparative Study of Neurofeedback for the Treatment of Parkinson's Disease

Osaka University2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2019年6月1日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施

试验速览

阶段
不适用
入组人数
20
试验地点
2
主要终点
Alteration of Brain Activities
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study aims to reveal relationship between brain activities and the symptoms of Parkinson disease when a neurofeedback training was applied for them.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 90 Years（Adult, Older Adult）
性别
All
接受健康志愿者
是

入选标准

  • •Subjects with age more than 20
  • •Subjects obtained the consent
  • •Subjects with Parkinson disease and healthy subjects

排除标准

  • •The subjects who can not conduct the tasks
  • •Subjects with severe illness
  • •Subjects whom the experimenter think as in appropriate
  • •Subjects with implantable devices such as pacemaker

研究组 & 干预措施

Training with Neurofeedback

Experimental

干预措施: Training with Neurofeedback (Other)

The other Training with Neurofeedback

Experimental

干预措施: The other Training with Neurofeedback (Other)

结局指标

主要结局

Alteration of Brain Activities

时间窗: At the time Immediately following the training

measured by magnetoencephalography

次要结局

  • The raw score change from baseline in the Movement disorder society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part Ⅲ scores(At the time Immediately following the training)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

已完成
4 期
Stalevo in Early Wearing-Off PatientsIdiopathic Parkinson's Disease
NCT00125567Orion Corporation, Orion Pharma223
已完成
3 期
Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson DiseaseParkinson Disease
NCT00558025Boehringer Ingelheim156
已完成
3 期
Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD PatientsEarly Parkinson Disease (Early PD)
NCT00479401Boehringer Ingelheim539
已完成
1 期
Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's DiseaseParkinson's Disease
NCT04157933Alexza Pharmaceuticals, Inc.35
已完成
不适用
PharmacoMRI of Parkinson DiseaseParkinson's Disease
NCT01528592Northwestern University18